Holen Sie sich die Stockscreener-App
76.19
1.59%
1.19
Handel nachbörslich:
76.21
0.02
+0.03%
Schlusskurs vom Vortag:
$75.00
Offen:
$75.23
24-Stunden-Volumen:
456.27K
Relative Volume:
0.52
Marktkapitalisierung:
$3.46B
Einnahmen:
$1.33B
Nettoeinkommen (Verlust:
$97.31M
KGV:
37.50
EPS:
2.0317
Netto-Cashflow:
$260.44M
1W Leistung:
+1.49%
1M Leistung:
-3.31%
6M Leistung:
-7.12%
1J Leistung:
-2.53%
1-Tages-Spanne:
$74.67
$76.58
1-Wochen-Bereich:
$71.81
$76.90
52-Wochen-Spanne:
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
Firmenname
Haemonetics Corp
Sektor
Branche
Telefon
(781) 848-7100
Adresse
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
76.19 | 3.46B | 1.33B | 97.31M | 260.44M | 2.0317 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-15 | Herabstufung | Needham | Buy → Hold |
| 2025-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Bestätigt | Barrington Research | Outperform |
| 2025-08-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-06-26 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-02-07 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-08 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Eingeleitet | CL King | Buy |
| 2024-09-11 | Eingeleitet | BofA Securities | Neutral |
| 2024-09-10 | Eingeleitet | BTIG Research | Buy |
| 2024-06-12 | Hochstufung | Needham | Hold → Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2022-01-27 | Herabstufung | Needham | Buy → Hold |
| 2021-12-15 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-08-17 | Fortgesetzt | Raymond James | Outperform |
| 2021-06-17 | Eingeleitet | Citigroup | Buy |
| 2021-05-14 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Hochstufung | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Eingeleitet | Needham | Buy |
| 2019-08-07 | Bestätigt | Barrington Research | Outperform |
| 2019-05-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Bestätigt | Barrington Research | Outperform |
| 2018-08-09 | Bestätigt | Barrington Research | Outperform |
| 2018-02-07 | Bestätigt | Barrington Research | Outperform |
| 2018-01-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Bestätigt | Barrington Research | Outperform |
| 2017-08-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Hochstufung | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Bestätigt | The Benchmark Company | Hold |
| 2016-09-20 | Herabstufung | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-08-02 | Bestätigt | Jefferies | Buy |
| 2016-08-02 | Bestätigt | The Benchmark Company | Hold |
Alle ansehen
Haemonetics Corp Aktie (HAE) Neueste Nachrichten
Haemonetics (HAE) Joins Russell Indexes As Investors Ask If The Stock Is Still Undervalued - simplywall.st
HAE stock holds steady as investors track Haemonetics' product mix - ad-hoc-news.de
Citi Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $79 - 富途牛牛
Haemonetics sets Aug. 6 call for Q1 2027 results - Stock Titan
Haemonetics (HAE) Analyst Adjusts Price Target Despite Neutral R - GuruFocus
Haemonetics Corp updates investors on blood management business. Operational focus supports long-ter - ad-hoc-news.de
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now? - Yahoo Finance
Haemonetics Corporation's $210 Million Cash Flow: Is The Transition Working? - Smartkarma
Daily Brief Health Care: Bausch Health Companies, Biodexa Pharmaceuticals, Fortrea Holdings , Haemonetics Corp, Legend Biotech Corp and more - Smartkarma
Haemonetics Corp updates plasma strategy, shares tracked against U.S. medtech peers - Ad-hoc-news.de
Haemonetics’ Broad Russell Value Index Inclusion Might Change The Case For Investing In Haemonetics (HAE) - simplywall.st
HAE Reiterated by BTIG -- Price Target Maintained at $84 - GuruFocus
Haemonetics Corp (HAE) Stock Up 6.5% and Still Undervalued -- GF Score: 84/100 - GuruFocus
[Latest] Global Therapeutic Apheresis Market Size/Share Worth USD 8.94 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Haemonetics Corp (HAE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mizuho Securities Maintains Haemonetics(HAE.US) With Buy Rating, Raises Target Price to $85 - 富途牛牛
Quietly ambitious, Haemonetics NexSys PCS pushes plasma efficiency further - AD HOC NEWS
Why Haemonetics’ NexSys PCS quietly reshapes plasma collection on the clinic floor - AD HOC NEWS
Haemonetics Corp (HAE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Haemonetics Corp (HAE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Haemonetics Corp (HAE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Haemonetics Corp (HAE) Institutional Confidence - TradingKey
Haemonetics Corp (HAE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Haemonetics Corp (HAE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Haemonetics Corp (HAE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Haemonetics Corp (HAE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Loomis Sayles Small Cap Core Portfolio's Haemonetics Corp(HAE) Holding History - GuruFocus
HAE Reiterated by BTIG -- Price Target Maintained at $84.00 - GuruFocus
Haemonetics Corp (HAE) Shares Fall 3.2% -- What GF Score of 77 T - GuruFocus
HAE: Upcoming Virtual Meeting Scheduled for June 24 - GuruFocus
HAE Maintained by Mizuho -- Price Target Raised to $85.00 - GuruFocus
Mizuho raises Haemonetics stock price target to $85 on plasma demand - Investing.com UK
HAE SEC FilingsHaemonetics Corp Mass 10-K, 10-Q, 8-K Forms - Stock Titan
Is Haemonetics’ (HAE) Apheresis Reorg Quietly Redefining Its Competitive Edge in Medical Devices? - simplywall.st
HAEMONETICS CORP ($HAE) President and CEO 2026 Pay Revealed - Quiver Quantitative
[ARS] HAEMONETICS CORP SEC Filing - Stock Titan
Executive pay and equity plans in Haemonetics (NYSE: HAE) 2026 proxy filing - Stock Titan
A Look At Haemonetics (HAE) Valuation After Its New Apheresis And MedSurg Segment Realignment - Yahoo Finance
A Look at Haemonetics Corp (HAE) After 5.0% Gain -- GF Value $84 - GuruFocus
Haemonetics (NYSE: HAE) VP settles RSU taxes with 259 withheld shares - Stock Titan
Haemonetics (HAE) SVP has 313 shares withheld for RSU tax obligations - Stock Titan
Haemonetics Corp at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Haemonetics Corp stock (US4041191090): solid growth story in blood management and plasma technology - Ad-hoc-news.de
Is Haemonetics (HAE) Stock Price Reflecting Its Recent 29% Monthly Surge Accurately - simplywall.st
Haemonetics Corp stock (US4041191090): segment restructuring shifts focus to Apheresis and MedSurg - Ad-hoc-news.de
Haemonetics Restructures Business Segments for Enhanced Efficien - GuruFocus
Haemonetics Updates Financial Reporting Segments, Combines Plasma and Blood Center Into Apheresis, Renames Hospital to MedSurg 1 - Minichart
Haemonetics restructures reporting segments from three to two - Investing.com
Haemonetics updates reporting structure, combines Plasma and Blood Center into Apheresis - TradingView
Haemonetics (NYSE: HAE) consolidates business into new Apheresis and MedSurg segments - Stock Titan
Haemonetics Updates Financial Reporting Segments - PR Newswire
Finanzdaten der Haemonetics Corp-Aktie (HAE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):